Advertisement

Hormontherapie

  • Elisabeth von der Lohe
Chapter
  • 16 Downloads

Zusammenfassung

Vor der Menopause ist das Auftreten einer KHK immer noch die Ausnahme. Nach der Menopause (dem Zeitpunkt der Reduktion der ovariellen Hormonproduktion) steigt die Prävalenz der KHK jedoch mit zunehmdendem Alter kontinuierlich an und erreicht bei Frauen über 75 Jahre das Niveau gleichaltriger Männer. Das Risiko der KHK ist bei jungen Frauen <35 Jahren) mit vorzeitiger oder chirurgisch induzierter Menopause und fehlender Hormonsubstitution um das Doppelte erhöht (Wenger et al. 1993). Diese Fakten haben zu der Annahme geführt, dass endogene Östrogene kardioprotektiv wirken und somit hauptverantwortlich für die geringe prämenopausale Prävalenz der KHK bei der Frau sind. In der Tat ist aber die Rolle der endogenen Hormone fü Pathogenese der KHK unklar.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Barrett-Connor E, Bush TL (1991) Estrogen and coronary heart disease in women. JAMA 265:1861–1867PubMedCrossRefGoogle Scholar
  2. Bergkvist L, Adami HO, Persson I et al. (1989) Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progesterone replacement therapy. AM J Epidemiol 130:221–228PubMedGoogle Scholar
  3. Blumenthal RS, Zacur HA, Reis SE, Post WS (2000) Beyond the null hypo thesis - Do the HERS results disprove the estrogen/coronary heart disease hypothesis? Am J Cardiol 85:1015–1017PubMedCrossRefGoogle Scholar
  4. Brett KM, Madans JH (1995) Long-term survival after coronary heart disease: comparisons between men and women in anational sampie. Ann Epidemiol 5:25–32PubMedCrossRefGoogle Scholar
  5. Bush TL (1991) Long-term effect of estrogen use on cardiovascular death in women. AHA Meeting, November 1991, Oriando/FLGoogle Scholar
  6. Bush TL, Barrett-Connor E, Cowan LO et al. (1987) Cardiovascular mortality and non-contraceptive estrogen use in women: results from the Lipid Research Clinics Program follow-up study. Circulation 75:1102–1109PubMedCrossRefGoogle Scholar
  7. Colditz GA, Hankinson SE, Hunter DJ et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589PubMedCrossRefGoogle Scholar
  8. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidermiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059CrossRefGoogle Scholar
  9. Collins P, Rosana G, Sarrel PM et al. (1995) Estrogen attenuates acetylcholineinduced coronary arterial constriction in women but not in men with coronary heart disease. Circulation 92:24–30PubMedCrossRefGoogle Scholar
  10. Criqui MH, Suwarez L, Barrett-Connor E et al. (1988) Postmenopausal estrogen use and mortality. Am J Epidemiol 128:606–614PubMedGoogle Scholar
  11. Cummings SR, Eckert S, Krueger KA et al. (1999) The effect of raloxifene on the risk of breast cancer in post-menopausal women: Results from the MORE (Multiple Outcomes ofRaloxifene Evaluation) trial. JAMA 281:2189PubMedCrossRefGoogle Scholar
  12. Cushman M, Legault C, Barrett-Connor E et al. (1999) Effect of postmenopausal hormones on inflammation-sensitive proteins: The postmenopausal estrogen/progestin interventions (PEPI) study.Circulation 100:717PubMedCrossRefGoogle Scholar
  13. Daly E, Vessey MP, Hawkins MM et al. (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348:977PubMedCrossRefGoogle Scholar
  14. Dupont WD, Page DL (1991) Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67–72PubMedCrossRefGoogle Scholar
  15. Fleming KC (1999) Hormone replacement therapy: practical prescribing. In: Charney P (ed) Coronary artery disease in women. American College of Physicians, Philadelphia, p 294Google Scholar
  16. Folsom AR, Mink PT, Seilers TA et al. (1995) Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Publ Health 85:1128–1132CrossRefGoogle Scholar
  17. Gerhard M, Ganz M (1995) How do we explain the clinical benefits of estrogen? Circulation 92:5PubMedCrossRefGoogle Scholar
  18. Gilligan DM, Quyyumi AA, Connon RO III (1994) Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89:2541–2551CrossRefGoogle Scholar
  19. Grady D, Rubin SM, Petitti DB et al. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women.Ann Intern Med 117:1016–1037PubMedGoogle Scholar
  20. Grady G, Gebretsadik T, Kerlikowske K et al. (1995) Hormone replacement therapy and endometrial cancer risk; A meta-analysis. Obstet Gynecol 85:304–313PubMedCrossRefGoogle Scholar
  21. Grady D, Hulley SB, Furberg C (1997) Venous thromboembolic events associated with hormone replacement therapy. JAMA 278:477PubMedCrossRefGoogle Scholar
  22. Grady D, Wenger NK, Herrington D et al. (2000) Postmenopausal hormone therapy increases risk for venous thrombembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 132:689–696PubMedGoogle Scholar
  23. Grodstein F, Stampfer MJ, Goldhaber SZ et al. (1996a) Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348:983PubMedCrossRefGoogle Scholar
  24. Grodstein F, Stampfer MJ, Manson JE et al. (1996b) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 332:1589Google Scholar
  25. Grodstein F, Stampfer MJ, Colditz GA et al. (1997) Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769PubMedCrossRefGoogle Scholar
  26. Grodstein F, Manson JE, Stampfer MJ et al. (1999) Postmenopausal hormones and recurrence of coronary events in the Nurses’ Health Study (abstract). Circulation 100: 1–871CrossRefGoogle Scholar
  27. Henderson BE, Paganini-Hill A, Ross RK. (1988) Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 159:312–317PubMedGoogle Scholar
  28. Henderson BE, Paganini-Hill A, Ross RK (1999) Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151:75–78CrossRefGoogle Scholar
  29. Herrington DM (1999) The HERS trial results: Paradigms lost? Ann Intern Med 131:463PubMedGoogle Scholar
  30. Herrington DM, Beboussin KB, Brosnihan KB et al. (2000) Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343:522–529PubMedCrossRefGoogle Scholar
  31. Herrington DM (2001) What about estrogens now? Curr J Rev 10(2)Google Scholar
  32. Hulley S, Grady D, Bush T et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605–613PubMedCrossRefGoogle Scholar
  33. Jick H, Derby LE, Myers MW et al. (1996) Risk of hospital admission for idiopathie venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981PubMedCrossRefGoogle Scholar
  34. Khovidhunkit W, Shoback DM (1999) Clinieal effects of raloxifene hydrochloride in women. Ann Intern Med 130:431PubMedGoogle Scholar
  35. Lobo RA: Hormones, hormone replacement therapy, and heart disease. In Douglas PS (ed): Cardiovascular Health and Disease in Women. WB Saunders, Philadelphia, 1993, p 153Google Scholar
  36. Love RR, Newcomb PA, Wiebe DA et al. (1990) Effects of tamoxifene therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer Inst 82:1327PubMedCrossRefGoogle Scholar
  37. Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801PubMedCrossRefGoogle Scholar
  38. Miller BA, Ries LAG, Hankey BF et al. (eds) (1992) Cancer Statisties Review: 1973-89. National Cancer Institute, Washington DC, NIH pub no 92, p 2789Google Scholar
  39. Nachtigall LE, Nachtigall RH, Nachtigall RD et al. (1979) Estrogen replacement therapy. Part II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54:74–79PubMedCrossRefGoogle Scholar
  40. Nachtigall M, Smilen SW, Nachtigall RD et al. (1992) Incidence ofbreast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 80:827–830PubMedGoogle Scholar
  41. Newton KM (1995) Estrogen replacement therapy and prognosis after first myocardial infarction [Abstract]. AHA Meeting, November 1995, San Diego/CAGoogle Scholar
  42. Pamela S, Douglas PS (2001) Coronary artery disease in women. In: Braunwald E, Zipes DP, Libby P (eds) Heart disease. Saunders, PhiladelphiaGoogle Scholar
  43. Reis SE, Gloth ST, Blumenthai RS et al. (1994) Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 89:52–60PubMedCrossRefGoogle Scholar
  44. Rieh-Edwards JW, Manson JE, Hennekens CH et al. (1995) The primary prevention of coronary heart disease in women. N Engl J Med 332:1758–1766CrossRefGoogle Scholar
  45. Ridker PM, Hennekens CN, Rifai N et al. (1999) Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100:713PubMedCrossRefGoogle Scholar
  46. Rutqvist LE, Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifene: The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398PubMedCrossRefGoogle Scholar
  47. Sack MN, Rader DJ, Cannon RO III (1994) Oestrogen and inhibition of oxidation oflow-density lipoproteins in postmenopausal women. Lancet 343:269–270PubMedCrossRefGoogle Scholar
  48. Stampfer MJ, Willett WC, Colditz GA et al. (1986) A prospective study of postmenopausal estrogen therapy, and coronary heart disease. N Engl J Med 313:1044–1049CrossRefGoogle Scholar
  49. Stampfer MJ, Colditz GA, Willett WC et al. (1991) Postmenopausal es trogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health study. N Engl J Med 325:756PubMedCrossRefGoogle Scholar
  50. Steinberg KK, Thacker SB, Smith JC (1991) A meta-analysis of the effect of estrogen replacement therapy on the risk ofbreast cancer. JAMA 265:1985–1990PubMedCrossRefGoogle Scholar
  51. Sullivan JM, Vander Zwaag R, Hughes JP et al. (1990) Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 150:2557–2562PubMedCrossRefGoogle Scholar
  52. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KK (1995) Estrogen replacement therapy after coronary artery bypass surgery: Effect on survival. Circulation 345:669Google Scholar
  53. The American-Canadian Cooperative Study Group (1986) Persantine Aspirin Trial in cerebral ischemia. Part III:Risk factors for stroke. Stroke 17:12–18CrossRefGoogle Scholar
  54. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogenl progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273:199–208CrossRefGoogle Scholar
  55. Walsh BW, Kuller LH, Wild RA et al. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445PubMedCrossRefGoogle Scholar
  56. Weiner CP, Lizasoain I, Baylis SA et al. (1994) Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 91:5212–5216PubMedCrossRefGoogle Scholar
  57. Wenger NK, Speroff L, Packard B (1993) Cardiovascular health and disease in women. N Engl J Med 329:247–526PubMedCrossRefGoogle Scholar
  58. Williams JK, Adams MR, Herrington DM, Clarkson TB (1992) Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 20:452–457PubMedCrossRefGoogle Scholar
  59. Wilson PWF, Garrison RJ, Castelli WP (1985) Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over so: the Framingham Study. N Engl J Med 313:1038–1043PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Elisabeth von der Lohe
    • 1
  1. 1.Wishard Health ServicesKrannert Institute of CardiologyIndianapolisUSA

Personalised recommendations